Glucagon-like peptide-1 receptor (GLP-1R) agonists are well established as an effective medication showing promising anti-diabetic effects in both animal models and patients with type 2 diabetes [158,159,160]. Here, GLP1R is linked to type 2 diabetes mellitus.